Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Jul 2019 15:34

Arix Bioscience Plc - Holding(s) in Company

Arix Bioscience Plc - Holding(s) in Company

PR Newswire

London, July 8

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Arix Bioscience Plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii: No trading in the stock - voting control interest over stock transferred to new managerX
3. Details of person subject to the notification obligationiv
NameWoodford Investment Management Ltd
City and country of registered office (if applicable)9400 Garsington Road, Oxford, OX4 2HN, United Kingdom
4. Full name of shareholder(s) (if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:05/07/2019
6. Date on which issuer notified (DD/MM/YYYY):08/07/2019
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached19.78%19.78%135,551,850
Position of previous notification (if applicable)21.89%21.89%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)Number of voting rightsix% of voting rights
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BD04507126,819,61719.78%
SUBTOTAL 8. A26,819,61719.78%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration datexExercise/ Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights
SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration datexExercise/ Conversion Period xiPhysical or cash settlementxiiNumber of voting rights % of voting rights
SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiiiX
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Woodford Investment Management Ltd19.780.0019.78
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi

Place of completion9400 Garsington Road, Oxford, OX4 2HN, United Kingdom
Date of completion08/07/2019
Date   Source Headline
22nd Jun 20224:45 pmEQSHolding(s) in Company
22nd Jun 20227:00 amEQSNotice of Investor Presentation
22nd Jun 20227:00 amEQSNotice of Investor Presentation
9th Jun 20227:00 amEQSUnaudited NAV for May 2022
9th Jun 20227:00 amEQSUnaudited NAV for May 2022
7th Jun 20224:45 pmEQSResult of Annual General Meeting 2022
12th May 20229:00 amRNSCommunications with Shareholders
12th May 20227:00 amRNSPublication of Annual Report & Notice of AGM
11th May 20227:01 amEQSUnaudited NAV for April
9th May 20223:29 pmEQSClinical Development Update from Portfolio Company LogicBio
5th May 20227:01 amEQSFinancial Results for the Year Ended 31 December 2021
4th May 20226:39 pmRNSStatement Regarding Arix Bioscience plc
4th May 20227:01 amEQSTR-1: Notification of major holdings
29th Apr 202210:45 amEQSUnaudited NAV and Notice of Financial Results
5th Apr 20224:29 pmEQSImara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
14th Mar 202211:32 amEQSCorporate update from portfolio company Harpoon Therapeutics
25th Feb 20225:30 pmRNSClosed Period Notification
24th Feb 20228:00 amRNSCompany Secretary Change
8th Feb 20227:20 amEQSTotal Voting Rights
2nd Feb 20221:06 pmEQSArix Bioscience PLC: Clinical development update from portfolio company LogicBio
22nd Dec 202111:05 amEQSArix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
17th Dec 202111:13 amEQSArix Bioscience PLC: Director/PDMR Shareholdings
17th Dec 20217:00 amRNSDirector/PDMR Shareholding
15th Dec 20218:14 amEQSArix Bioscience PLC: Depixus raises €30.6M (£26.1 million) in Series A Financing
13th Dec 20213:54 pmEQSArix Bioscience PLC: Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
13th Dec 20213:51 pmEQSArix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021
17th Nov 20215:04 pmEQSImara Announces Interim Analysis Data From Forte Phase 2b Clinical Trial Of Tovinontrine (Imr-687) In Transfusion-Dependent Subjects With Beta-Thalassemia
8th Nov 20215:34 pmEQSTransaction in own shares
8th Nov 20211:00 pmEQSArix Bioscience PLC: Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
8th Nov 20217:01 amEQSArix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference
1st Nov 20217:01 amEQSTotal Voting Rights
29th Oct 20217:00 amEQSAura Biosciences prices Nasdaq IPO
18th Oct 20214:48 pmEQSLogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
18th Oct 20217:00 amEQSBusiness Update and Cancellation of Share Buyback
15th Oct 20215:30 pmEQSTransaction in own shares
14th Oct 20215:30 pmEQSTransaction in own shares
13th Oct 20215:30 pmEQSTransaction in own shares
13th Oct 20215:28 pmEQSTR1: Notification of Major Shareholding
12th Oct 20215:30 pmEQSTransaction in own shares
12th Oct 20211:02 pmEQSAura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting
11th Oct 20215:30 pmEQSTransaction in own shares
8th Oct 20215:30 pmEQSTransaction in own shares
8th Oct 202110:11 amEQSPyxis Oncology prices Nasdaq IPO - Update
8th Oct 20217:00 amEQSPyxis Oncology prices Nasdaq IPO
7th Oct 20215:30 pmEQSTransaction in own shares
6th Oct 20215:30 pmEQSTransaction in own shares
6th Oct 20217:00 amEQSBoard Changes
5th Oct 20215:30 pmEQSTransaction in own shares
4th Oct 20215:30 pmEQSTransaction in own shares
1st Oct 20215:30 pmEQSTransaction in own shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.